Product Description
Pegylated Somatropin. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT02976675)
Mechanisms of Action: GHR Replacer
Novel Mechanism: Yes
Modality: Coagulation Factor
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Changchun GeneScience Pharmaceutical Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Hypopituitarism
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ELEVATE | P3 |
Not yet recruiting |
Hypopituitarism |
2025-05-01 |